What Should You Do If IVIg or Steroids Fail for CIDP?

If your symptoms are not improving with standard Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatments like intravenous immunoglobulin (IVIg) or corticosteroids, the most important next step is to have your diagnosis reassessed by a neuromuscular specialist ^[1][2]. Poor treatment response does not automatically mean you need a higher dose or a stronger drug.

In some specialized referral centers, a substantial number of patients (up to half in one study) referred for “treatment-resistant CIDP” were found to actually have an alternative diagnosis ^[3]. Your doctor should verify that your treatment trial was adequate, reconsider your original test results, and check for “CIDP mimics” before making major changes to your care plan.

What Does “Working” Look Like?

Before changing treatments, it is vital to define what success looks like. Sometimes, a treatment is “working” by stabilizing your disease and preventing further decline, rather than restoring lost strength. If you have permanent nerve fiber loss (axonal damage), you may have residual numbness or weakness even when the treatment has successfully stopped the inflammation ^[4]. A lack of complete recovery does not always mean the treatment failed.

Was the Treatment Trial Adequate?

Before deciding that a treatment has failed, your care team must ensure that it was given a fair chance to work based on your specific case:

• Dose and Duration: A proper trial requires your clinician to define the dose, interval, and objective endpoint in advance. While IVIg responses are often assessed over several cycles, there is no single trial duration that fits everyone ^[5]. Corticosteroids may also have a different timeline for showing benefit depending on the regimen ^[6]. However, prolonged treatment without any benefit can expose you to unnecessary risks and delay the discovery of a different diagnosis.
• Objective Measurement: It is crucial to measure your response using validated, objective tools—such as grip strength testing (dynamometry), standardized disability scores (like INCAT or I-RODS), or timed walking tests ^[4][7]. If there is zero objective improvement and your condition is still worsening, it should prompt a careful reassessment of your diagnosis ^[4].
• Adherence and Timing: If doses were skipped, delayed, or given at an insufficient maintenance level, you might simply be undertreated rather than treatment-resistant ^[8].

Is the Diagnosis Correct?

If your treatment trial was sufficient but you still haven’t improved, your doctor should re-review your original nerve-conduction studies and clinical symptoms ^[3].

CIDP is a complex disease, and some test results can be easily misinterpreted. For example, isolated abnormalities on a nerve test, a mild elevation of protein in the cerebrospinal fluid (the fluid surrounding your brain and spinal cord), or nerve slowing caused by natural compression points do not guarantee a CIDP diagnosis ^[9][10]. A specialist will likely compare your original nerve tests against the 2021 guidelines from the European Academy of Neurology and Peripheral Nerve Society (EAN/PNS) to see if the overall pattern truly indicates acquired demyelination (damage to the nerve’s protective coating) ^[11].

Alternative Diagnoses to Consider (The Mimics)

Many nerve disorders look like CIDP initially but do not respond to IVIg or steroids. Identifying these mimics is critical because they require completely different treatment approaches:

• Autoimmune Nodopathies: These are distinct antibody-associated disorders where antibodies (like anti-NF155 or anti-CNTN1) attack the nodes of Ranvier (the unprotected gaps in the nerve’s myelin coating). Patients often have severe weakness in the hands and feet, sensory ataxia (severe loss of coordination), and tremors ^[12][13]. Standard CIDP treatments often fail, but specialists might use plasma exchange or B-cell-targeted therapies (like rituximab), though these are off-label and carry notable infection risks ^[13][14].
• Anti-MAG Neuropathy: This is a slowly progressive neuropathy that is primarily sensory, often featuring tremors, ataxia, and an IgM monoclonal protein (an abnormal blood protein) ^[15]. Finding this protein usually prompts an evaluation by a hematologist (blood specialist) ^[16].
• Multifocal Motor Neuropathy (MMN): MMN typically causes asymmetrical weakness (affecting one side of the body more than the other) and specifically affects motor nerves ^[17]. Crucially, corticosteroids generally do not help MMN and can actually make weakness worse, whereas IVIg is commonly used for this condition ^[17].
• Hereditary Neuropathies: Genetic conditions, such as Charcot-Marie-Tooth (CMT) disease, can closely mimic the nerve-test results of CIDP ^[18]. Clues include a very slow progression, pes cavus (high foot arches), or spinal deformities ^[18]. While a family history is a strong clue, its absence does not rule out a genetic cause, and genetic testing may be considered ^[18][19].

Next Steps: Changing Therapies

If a specialist thoroughly reviews your case and confirms that you definitely have CIDP, they may adjust your treatment. According to the 2021 EAN/PNS guidelines, if you do not respond to one first-line treatment (like IVIg), you might still respond to another (like corticosteroids) ^[11].

If both IVIg and corticosteroids are genuinely ineffective, plasma exchange (PLEX)—a procedure that filters your blood to remove harmful antibodies—is a guideline-supported option to discuss ^[11]. However, PLEX is not a simple next drug; it requires specialized vascular access and carries burdens such as low blood pressure, fluid shifts, and infection risks. In some cases, specialists may consider adding immunosuppressive drugs, but the evidence for these is limited, they are often off-label, and they carry substantial drug-specific risks ^[11].

Safely Changing Treatments and Urgent Care

Do not change or stop any treatment without contacting your prescriber.
Stopping systemic corticosteroids abruptly can cause adrenal insufficiency—a dangerous hormonal imbalance that must be prevented by medically supervised tapering ^[20]. While spacing or stopping IVIg does not cause hormonal withdrawal, it must be monitored closely to ensure your underlying disease does not rapidly relapse ^[21][22].

When to Seek Urgent Care:
While slow or absent improvement is discouraging, sudden deterioration is a medical emergency. Seek immediate or emergency medical care if you experience:

• Rapidly progressive weakness
• New trouble breathing or swallowing
• Sudden inability to stand or walk safely
• Repeated falls

Always contact your treating team promptly for any slower but clear decline in your function.